Welcome to Helix Talk, a podcast presented by the Rosalm Franklin University College of Pharmacy.

This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics.

We're hoping that our real-life clinical pearls and discussions will help you stay up to date

and improve your pharmacy knowledge.

This is an educational production copyright Rosalind Franklin University of Medicine and Science.

This podcast contains general information for educational purposes only. This is not professional advice and should not be used in lieu of obtaining advice from a qualified health care provider.

And now, on to the show.

Welcome to episode 12 of Helix Talk. I'm your co-host Dr. Kane. I'm Dr. Schumann.

And I'm Dr. Patel.

Today we're talking about osteoporosis. And we're going to briefly discuss kind of the go-to

therapies for osteoporosis, but we're really going to focus on two newer agents. The brain

name is Prolia or Dynastomab. And then the other agent is for Teo or Terioparotide.

And if you think about what main governing body, who is responsible for publishing the

practicing guideline for osteoporosis, we have the National Asteroosis Foundation, NOF.

The recent guidelines are updated in April 2014, and they are focused more towards patients who are

driven 50 years of age. As you can imagine, this condition comes with the increased age and

post-menopausal status. It's kind of nice to see updated guidelines. You know, we talked about

the H-CAP-VAP, HAP, and CAP guidelines, which were quite old, almost a decade old. So it's

nice to see guidelines

being updated as new drug therapies come out and new evidence comes out.

So I think one of the first places that kick off is to talk about what exactly is osteoporosis.

So I know if you look at the breakdown of the word, we can think of osteo meaning bone and

...